☆ 4.4 Article

Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer

CLINICAL LUNG CANCER (2019)

Get Full Text
Add to Collection

Journal

CLINICAL LUNG CANCER
Volume 20, Issue 5, Pages E555-E559

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2019.06.021

Keywords

ALK-TKI; MET; Mutation; NGS; Sequential treatment

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.